Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Assets Average (2016 - 2025)

RedHill Biopharma has reported Assets Average over the past 13 years, most recently at $21.9 million for Q4 2025.

  • Quarterly Assets Average rose 9.12% to $21.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.9 million through Dec 2025, up 9.12% year-over-year, with the annual reading at $21.7 million for FY2025, 5.59% up from the prior year.
  • Assets Average was $21.9 million for Q4 2025 at RedHill Biopharma, up from $18.2 million in the prior quarter.
  • Over five years, Assets Average peaked at $211.9 million in Q2 2021 and troughed at $18.2 million in Q2 2025.
  • The 5-year median for Assets Average is $158.0 million (2022), against an average of $114.7 million.
  • Year-over-year, Assets Average surged 84.01% in 2021 and then tumbled 81.62% in 2023.
  • A 5-year view of Assets Average shows it stood at $183.8 million in 2021, then dropped by 14.0% to $158.0 million in 2022, then tumbled by 81.62% to $29.0 million in 2023, then tumbled by 31.02% to $20.0 million in 2024, then increased by 9.12% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Assets Average are $21.9 million (Q4 2025), $18.2 million (Q2 2025), and $20.0 million (Q4 2024).